ANTI-TOPOISOMERASE POSITIVE SYSTEMIC SCLEROSIS PROGNOSIS INFAUST?

被引：0
|
作者：
Boonstra, M. [1 ]
Beerends, G. A. [1 ]
Scherer, H. U. [1 ]
de Vries-Bouwstra, J. K. [1 ]
机构：
[1] LUMC, Rheumatol, Leiden, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.6414
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0650
引用
收藏
页码：1279 / 1280
页数：2
相关论文
共 50 条
  • [31] Anti-topoisomerase 1 Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis
    L. P. Ananyeva
    L. A. Garzanova
    O. A. Koneva
    M. N. Starovoytova
    O. V. Desinova
    O. B. Ovsyannikova
    R. U. Shayakhmetova
    M. V. Cherkasova
    A. P. Aleksankin
    E. L. Nasonov
    Doklady Biochemistry and Biophysics, 2023, 511 : 212 - 218
  • [32] Association of HLA-DR with anti-topoisomerase I antibody in Korean patients with systemic sclerosis.
    Song, YW
    Lee, EB
    Kang, SH
    Park, MH
    Takeuchi, F
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S204 - S204
  • [33] Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria
    Boonstra, Maaike
    Ninaber, Maarten K.
    Marsan, Nina Ajmone
    Huizinga, Tom W. J.
    Scherer, Hans Ulrich
    de Vries-Bouwstra, Jeska K.
    RHEUMATOLOGY, 2019, 58 (04) : 730 - 732
  • [34] Anti-topoisomerase 1 Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis
    Ananyeva, L. P.
    Garzanova, L. A.
    Koneva, O. A.
    Starovoytova, M. N.
    Desinova, O. V.
    Ovsyannikova, O. B.
    Shayakhmetova, R. U.
    Cherkasova, M. V.
    Aleksankin, A. P.
    Nasonov, E. L.
    DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2023, 511 (01) : 212 - 218
  • [35] Antinuclear autoantibody profile in systemic sclerosis patients who are negative for anticentromere and anti-topoisomerase I specificities
    Caramaschi, Paola
    Tonolli, Elisabetta
    Biasi, Domenico
    Caimmi, Cristian
    Pieropan, Sara
    Dal Forno, Ilaria
    Scambi, Cinzia
    Adami, Silvano
    JOINT BONE SPINE, 2015, 82 (03) : 209 - 210
  • [36] Multi-omics Study of Systemic Sclerosis Immunoglobulins G Effects on Endothelial Cells: A Distinct Profile in Anti-Topoisomerase I Positive Patients
    Chepy, Aurelien
    Vivier, Solange
    Elhannani, Abderrahmane
    Bray, Fabrice
    Chauvet, Clement
    Figeac, Martin
    Guilbert, Lucile
    Hachulla, Eric
    Rolando, Christian
    Dubucquoi, Sylvain
    Launay, David
    Sobanski, Vincent
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1984 - 1986
  • [37] Anti-topoisomerase II α autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35
    Grigolo, B
    Mazzetti, I
    Meliconi, R
    Bazzi, S
    Scorza, R
    Candela, M
    Gabrielli, A
    Facchini, A
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 121 (03): : 539 - 543
  • [38] Anti-topoisomerase-positive limited systemic sclerosis has a propensity for interstitial lung disease but is linked to favourable prognosis
    Desai, Ruhani P.
    Assassi, Shervin
    RHEUMATOLOGY, 2022, 61 (12) : 4585 - 4586
  • [39] Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis
    Gourh, Pravitt
    Tan, Filemon K.
    Assassi, Shervin
    Ahn, Chul W.
    McNearney, Terry A.
    Fischbach, Michael
    Arnett, Frank C.
    Mayes, Maureen D.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (12): : 3945 - 3953
  • [40] A distinct syndrome including features of systemic sclerosis, erosive rheumatoid arthritis, anti-topoisomerase antibody, and rheumatoid factor
    Doran, M
    Wordsworth, P
    Bresnihan, B
    FitzGerald, O
    JOURNAL OF RHEUMATOLOGY, 2001, 28 (04) : 921 - 922
12345